```
Page 1
                          SARA QUINNEY
            UNITED STATES PATENT AND TRADEMARK OFFICE
            BEFORE THE PATENT TRIAL AND APPEAL BOARD
3
5
    AMNEAL PHARMACEUTICALS LLC, )
6
                 Petitioner, ) CASE NO.
7
                                  ) IPR2018-00943
              -v-
                                  ) Patent No.
    ALKERMES PHARMA IRELAND
                                ) 7,919,499
    LIMITED,
10
                 Patent Owner.
11
12
13
            The deposition upon oral examination of
14
    SARA QUINNEY, Ph.D., a witness produced and sworn
15
    before me, Debbi S. Austin, RMR, CRR, Notary Public in
16
    and for the County of Hendricks, State of Indiana,
17
    taken on behalf of the Petitioner at the offices of
    Harrison & Moberly, 10 West Market Street, Suite 700,
18
19
    Indianapolis, Indiana, on May 24, 2019, at 9:30 a.m.,
20
    pursuant to the Federal Rules of Civil Procedure.
21
22
23
24
25
    Job No. 161382
```


TSG Reporting - Worldwide 877-702-9580



```
Page 2
 1
                           SARA QUINNEY
 2
                            APPEARANCES
 3
 4
     FOR THE PETITIONER:
          Michael Stramiello, Ph.D., Esq.
          PAUL HASTINGS
 б
          875 15th Street, N.W.
          Washington, DC 20005
 7
          Gerard Salvatore, Esq.
 8
          PAUL HASTINGS
          200 Park Avenue
 9
          New York, NY 10166
10
     FOR THE PATENT OWNER:
11
          Tedd Van Buskirk, Esq.
12
          LERNER, DAVID, LITTENBERG,
          KRUMHOLZ & MENTLIK
13
          600 South Avenue West
          Westfield, NJ 07090
14
15
     ALSO PRESENT: John W. Kirkland, Alkermes
16
17
18
19
20
21
22
23
24
25
```



|                |                              |  |      | Page 3 |
|----------------|------------------------------|--|------|--------|
| 1              |                              | SARA QUINNEY   |      |        |
| 2              |                              | INDEX OF EXAMINATION   |      |        |
| 3              |                              |  | PAGE |        |
| 4              | EXAMINATION                  |  |      |        |
| 5              | Questions By Mr. Stramiello: |  |      |        |
| 6              |                              |  |      |        |
| 7              |                              |  |      |        |
| 8              |                              |  |      |        |
| 9              |                              |  |      |        |
| 10             |                              | THEN OF THUTPER  |      |        |
| 11             |                              | INDEX OF EXHIBITS  |      |        |
| 12             | NUM.                         | DESCRIPTION  | PAGE |        |
| 13             | Exhibit 1001                 | U.S. Patent No. 7,919,499  | 39   |        |
| 14             | Exhibit 1010                 | "Depot Naltrexone:<br>Long-lasting antagonism of the<br>effects of heroin in humans"                                 | 49   |        |
| 15             | Exhibit 1014                 | U.S. Patent No. 7,157,102  | 49   |        |
| 16<br>17<br>18 | Exhibit 1062                 | Declaration of Sara K. Quinney,<br>Pharm.D., Ph.D. in Support of<br>Petitioner's Reply to Patent<br>Owner's Response | 30   |        |
| 19             | Exhibit 1063                 | Curriculum Vitae   | 7    |        |
| 20             | Exhibit 1064                 | "Effect of liver cirrhosis on  | 56   |        |
| 21             |                              | the systemic availability of naltrexone in humans"   |      |        |
| 22             | Exhibit 1081                 | "Naltrexone: A review of   | 55   |        |
| 23             |                              | existing sustained drug delivery systems and emerging nano-based systems"  |      |        |
| 24             |                              | -  |      |        |
| 25             |                              |  |      |        |



|        |              |   |      | Page 4 |
|--------|--------------|---|------|--------|
| 1      |              | SARA QUINNEY  |      |        |
| 2      |              | INDEX OF EXHIBITS (CONT'D.)   |      |        |
| 3      | NUM.         | DESCRIPTION   | PAGE |        |
| 4<br>5 | Exhibit 2017 | "Naltrexone: Disposition, metabolism, and effects after acute and chronic dosing"                             | 52   |        |
| 6<br>7 | Exhibit 2028 | "Bioequivalence,<br>Dose-Proportionality, and<br>Pharmacokinetics of Naltrexone<br>after Oral Administration" | 60   |        |
| 9      | Exhibit 2038 | "Narcotic Antagonists:<br>Naltrexone Pharmacochemistry<br>and Sustained-Release<br>Preparations"              | 57   |        |
| 11     |              | 1105010010  |      |        |
| 12     |              |   |      |        |
| 13     |              |   |      |        |
| 14     |              |   |      |        |
| 15     |              |   |      |        |
| 16     |              |   |      |        |
| 17     |              |   |      |        |
| 18     |              |   |      |        |
| 19     |              |   |      |        |
| 20     |              |   |      |        |
| 21     |              |   |      |        |
| 22     |              |   |      |        |
| 23     |              |   |      |        |
| 24     |              |   |      |        |
| 25     |              |   |      |        |



- 1 SARA QUINNEY
- SARA QUINNEY, Ph.D.,
- 3 having been first duly sworn to tell the truth, the
- 4 whole truth, and nothing but the truth, was examined
- 5 and testified as follows:
- 6 EXAMINATION
- <sup>7</sup> BY MR. STRAMIELLO:
- 8 Q Good morning, Dr. Quinney. Would you please state
- and spell your name and home address for the
- 10 record.
- 11 A Sure. It's Sara Quinney, S-A-R-A, Q-U-I-N-N-E-Y,
- and my home address is 2384 Smith Road, Plainfield,
- 13 Indiana.
- 14 Q Thank you.
- And you're here for petitioner, Amneal
- Pharmaceuticals, LLC; correct?
- <sup>17</sup> A Correct.
- 18 Q Do you understand that you're under oath today?
- $^{19}$  A Yes.
- 20 Q Is there any reason why you cannot provide honest
- and complete testimony today?
- <sup>22</sup> A No.
- 23 Q Let's go over a few ground rules. First, I plan a
- few breaks. If you need additional ones, please
- just let me know.



# DOCKET

# Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

# **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

### **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

